Suzanne Topalian


1984 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Suzanne Topalian is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 8 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Defining tumor resistance to PD-1 pathway blockade: Recommendations from the first meeting of the SITC Immunotherapy Resistance Taskforce

Kluger, H. M., Tawbi, H. A., Ascierto, M. L., Bowden, M., Callahan, M. K., Cha, E., Chen, H. X., Drake, C. G., Feltquate, D. M., Ferris, R. L., Gulley, J. L., Gupta, S., Humphrey, R. W., Lavallee, T. M., Le, D. T., Hubbard-Lucey, V. M., Papadimitrakopoulou, V. A., Postow, M. A., Rubin, E. H., Sharon, E. & 5 others, Taube, J. M., Topalian, S., Zappasodi, R., Sznol, M. & Sullivan, R. J., Apr 1 2020, In : Journal for immunotherapy of cancer. 8, 1, e000398.

Research output: Contribution to journalArticle

Open Access
  • Neoadjuvant checkpoint blockade for cancer immunotherapy

    Topalian, S. L., Taube, J. M. & Pardoll, D. M., Jan 31 2020, In : Science. 367, 6477, eaax0182.

    Research output: Contribution to journalReview article

  • Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy

    Nghiem, P., Bhatia, S., Lipson, E. J., Sharfman, W. H., Kudchadkar, R. R., Brohl, A. S., Friedlander, P. A., Daud, A., Kluger, H. M., Reddy, S. A., Boulmay, B. C., Riker, A. I., Burgess, M. A., Hanks, B. A., Olencki, T., Margolin, K., Lundgren, L. M., Soni, A., Ramchurren, N., Church, C. & 11 others, Park, S. Y., Shinohara, M. M., Salim, B., Taube, J. M., Bird, S. R., Ibrahim, N., Fling, S. P., Moreno, B. H., Sharon, E., Cheever, M. A. & Topalian, S. L., Mar 20 2019, In : Journal of Clinical Oncology. 37, 9, p. 693-702 10 p.

    Research output: Contribution to journalArticle

  • Five-Year Survival and Correlates among Patients with Advanced Melanoma, Renal Cell Carcinoma, or Non-Small Cell Lung Cancer Treated with Nivolumab

    Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Sosman, J. A., Atkins, M. B., Leming, P. D., Spigel, D. R., Antonia, S. J., Drilon, A., Wolchok, J. D., Carvajal, R. D., McHenry, M. B., Hosein, F., Harbison, C. T., Grosso, J. F. & Sznol, M., Oct 2019, In : JAMA Oncology. 5, 10, p. 1411-1420 10 p.

    Research output: Contribution to journalArticle